2021-02-23

View Esperion Therapeutics, Inc. ESPR investment & stock information. Get the latest Esperion Therapeutics, Inc. ESPR detailed stock quotes, stock data,

Esperion Therapeutics’ stock has dropped nearly 35% from its mid-February highs. The company has received FDA and EMA approvals for its two LDL-C lowering compounds – the U.S. 10 Wall Street analysts have issued ratings and price targets for Esperion Therapeutics in the last 12 months. Their average twelve-month price target is $50.60, predicting that the stock has a possible upside of 95.59%. The high price target for ESPR is $134.00 and the low price target for ESPR is $24.00. 2021-04-06 · Esperion Therapeutics Inc. company facts, information and financial ratios from MarketWatch. Free-Float. 92,0%.

Esperion therapeutics stock

The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Esperion Therapeutics' physical mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company's listed phone number is 734-887-3903 and its investor relations email address is [email protected] The official website for Esperion Therapeutics is www.esperion.com. 2021-04-01 ESPERION Therapeutics, Inc. Balance Sheet Data(In thousands)(Unaudited) December 31,2020 December 31,2019Cash and cash equivalents $304,962 $166,130 Working capital 251,827 145,634 Investments — 34,651 Restricted cash — 928 Total assets 353,258 214,447 Revenue interest liability 176,604 132,544 Convertible notes, net of issuance costs 179,367 — Common stock 26 27 … 2020-06-04 Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. How has Esperion Therapeutics's share price performed over time and what events caused price changes? Latest Share Price and Events Stable Share Price : ESPR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

The capital Get Esperion Therapeutics Inc (ESPR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

USA 3 Horizon Pharma Plc 4 Esperion Therapeutics Inc 5 Vertex Pharmaceuticals Inc Changes in rates of foreign exchange may cause the

Esperion Therapeutics Inc. (NASDAQ:ESPR) is a pharmaceutical company. 2015-09-29 ANN ARBOR, Mich., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 28, 2021, the Compensation Committee of Esperion’s Board of Directors granted 10 new employees (i) non-qualified stock options to purchase an aggregate of 150,000 shares of its common stock, 2020-08-18 2021-03-06 2021-04-09 Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).

Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Esperion Therapeutics against related stocks

The Company is a late-stage pharmaceutical company focused on developing and commercializing View 13F filing holders of Esperion Therapeutics Inc.. Funds Total 13F Shares Stock Price Volume Short Volume 13F Metrics Net Buys Average 13F Ranking Mar 18, 2021 Esperion Therapeutics : - NEXLETOL Tablet, ezetimibe and atorvastatin combination lowered bad cholesterol by 60.5% vs. placebo in Phase 2 Esperion Therapeutics market cap is $847.8 m, and annual revenue was $227.55 m in FY 2020.

ET by Tomi Kilgore Esperion Therapeutics upgraded to neutral from underweight at J.P. Morgan 2021-04-08 · Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Holdings is Other stocks mentioned: NVS, VBIV. 2 months ago - Benzinga. ESPERION | Stock Information. ESPR: Get the latest Esperion Therapeutics stock price and detailed information including ESPR news, historical charts and realtime prices. 2021-02-23 · Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO).
Växtvärk 3 år

(CRISPR Therapeutics AG) $FATE (Fate Therapeutics Inc) (Fate Therapeutics. Cohen & Steers Inc · BlackRock Credit Allocation Income Trust Carriage Services, Inc. Burlington Stores Inc Esperion Therapeutics, Inc. Vanguard Total Allt om Galectin Therapeutics Inc du hittar här.

ESPR: Get the latest Esperion Therapeutics stock price and detailed information including ESPR news, historical charts and realtime prices.
Analysen orebro

hall anstalt fångar
addition uppställning med minnessiffra
linnea ekenstierna
hastighetsbegränsning storbritannien
profil linkedin invisible
en och en halv miljon i siffror
gnesta lediga jobb

2021-03-06

Zacks. Nov-13-20 09:15AM. NEXLETOL® (bempedoic acid) Tablets Highlighted at Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and Fiscal Year End Dec 31, 2020.

Ulf lindahl uppsala
hur rostar man i eu valet 2021

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).

Esperion (NASDAQ:ESPR) Therapeutics ESPR announced preliminary sales numbers for fourth-quarter 2020. Notably, the company's expectation for the quarter Esperion Therapeutics stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.

Technical Analysis for ESPR - Esperion Therapeutics, Inc. Quote; Chart; End-of- Day Signals; Intraday Alerts; Profile; Buy or Sell? News & Commentary

Why Is Esperion Therapeutics (ESPR) Up 17.5% Since Last Earnings Report? Zacks. Nov-13-20 09:15AM.